GLP-1 Through Direct-to-Consumer: How It Works

Introduction

Direct-to-consumer GLP-1 is the model that emerged between 2022 and 2026. A patient signs up online, completes an intake, gets reviewed by a licensed clinician via telehealth, receives a prescription, and the medication ships from a partner pharmacy. No primary care referral, no in-person visit, no insurance prior authorization unless the patient wants to use coverage. The model exists in two forms: brand-name DTC (LillyDirect, NovoCare) and compounded DTC (TrimRx, Hims, Henry Meds, Mochi Health, and a few dozen others).

The DTC model isn’t loose. Every legitimate platform involves licensed prescribers in each state where the patient is located, US-licensed pharmacies, and clinical documentation that would hold up in an audit. The flexibility compared to traditional insurance is real, but the underlying clinical standards aren’t optional.

This guide walks through how DTC GLP-1 actually works in 2026, what’s behind the scenes, and the regulatory rules that separate legitimate platforms from gray-market vendors.

At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.

What Is Direct-to-consumer GLP-1?

DTC GLP-1 means a model where the patient interacts directly with a telehealth platform (rather than going through traditional primary care or specialty referrals) to get a prescription. The platform handles intake, clinician matching, prescription writing, and pharmacy coordination. The patient pays cash (typically) and the medication ships to their home.

Quick Answer: DTC GLP-1 in 2026 has two paths: brand-name (LillyDirect for Zepbound® vials, NovoCare for Wegovy®) and compounded (TrimRx, Hims, Henry Meds, etc.)

Two business models exist:

• Manufacturer DTC: LillyDirect (Eli Lilly’s program for Zepbound vials, run through a partnership with Form Health) and NovoCare (Novo Nordisk’s program for Wegovy)
• Independent telehealth DTC: TrimRx, Hims, Henry Meds, Mochi Health, Ro, Found, and others, mostly prescribing compounded GLP-1 from US 503A pharmacies

Both models exist legitimately in 2026. The difference is who manufactures the product (Lilly/Novo for brand, a US 503A pharmacy for compounded) and how the clinical work-up is handled.

Who Can Legally Run a DTC GLP-1 Platform?

Three pieces are required. First, a licensed clinician (MD, DO, NP, or PA depending on state scope-of-practice rules) in every state where the platform writes prescriptions. The clinician reviews the case and writes the prescription. The platform employs or contracts with clinicians, not the other way around.

Second, a US-licensed pharmacy. For brand-name, this is typically a mail-order specialty pharmacy that dispenses pen or vial. For compounded, it’s a 503A pharmacy that prepares the medication for the individual patient. Both must hold active state pharmacy licenses.

Third, telehealth-compliant intake and documentation. The asynchronous medical visit must capture enough history for the clinician to make a reasonable prescribing decision. The platform must store records consistent with state medical practice rules.

Operating without all three is illegal. Many of the FDA warning letters in 2024-2025 went to “peptide vendors” that lacked one or more of these elements.

How Does LillyDirect Work?

LillyDirect launched in 2024 as Eli Lilly’s direct channel for Zepbound vials. The patient signs up at lillydirect.com, completes a medical visit through a partner telehealth platform (Form Health for the GLP-1 program), and the prescription is filled through Lilly’s specialty pharmacy network.

Pricing in mid-2026: 2.5 mg vials at $349/month, 5 mg and 7.5 mg at $499, 10 mg at $599, 12.5-15 mg at $699. Vials require self-drawing with a 1 mL syringe (provided in the kit). The clinical visit asks for BMI, history, and labs in many cases.

LillyDirect is structurally similar to compounded DTC platforms (intake → clinician → pharmacy → ship), but the product is FDA-approved Zepbound rather than compounded tirzepatide. Speed is comparable. Price is higher than compounded.

How Does NovoCare Work?

NovoCare expanded in 2024-2025 to include direct-to-consumer Wegovy self-pay options. The structure is similar to LillyDirect: online intake, clinician review, prescription fulfilled by Novo’s specialty pharmacy network. Pricing for Wegovy self-pay through NovoCare is around $499/month at all doses in 2026.

For patients who specifically want brand-name Wegovy without going through insurance or traditional pharmacy channels, NovoCare is the cleanest path.

How Does Compounded DTC Work?

Compounded DTC platforms (TrimRx, Hims, Henry Meds, Mochi Health, Form Health’s compounded track, Ro’s compounded track, Found’s compounded track) follow a similar workflow but use a US 503A compounding pharmacy as the dispenser.

The workflow:

1. Patient completes intake on the platform’s website. Captures BMI, medical history, medications, allergies, contact info, sometimes a photo ID.
2. Licensed clinician in the patient’s state reviews the case. Asynchronous review usually within 24-48 hours, sometimes within hours for streamlined platforms.
3. Clinician writes the prescription if clinically appropriate and documents the individualized clinical need (required post-FOAF ruling).
4. Prescription transmits to the partner 503A pharmacy.
5. Pharmacy prepares the medication, packages it with syringes and instructions, and ships in temperature-controlled overnight packaging.
6. Patient receives in 5-10 days from start, sometimes 3-5 days at fast platforms.

The platform handles billing (cash, HSA, or sometimes split with insurance) and follow-up support.

What Does the Asynchronous Medical Visit Look Like?

The intake captures the same information a clinician would gather in an office visit but in form format. Typical fields:

• Demographics, height, weight, BMI calculation
• Current medications and allergies
• Past medical history (cardiovascular, kidney, thyroid, GI, pancreatitis, MEN-2 family history)
• Past surgical history including bariatric procedures
• Weight history and prior weight loss attempts
• Pregnancy status and birth control
• Mental health history (eating disorders are a specific screen)
• Lab values if requested (usually optional at no-labs platforms)
• Acknowledgment of risks and consent to telehealth treatment

The clinician reviews and may message the patient with follow-up questions before approving or declining.

Key Takeaway: The March 2025 FOAF v. FDA ruling narrowed compounded GLP-1 to individualized 503A prescriptions with documented clinical need

What Changed After the March 2025 Court Ruling?

The Outsourcing Facilities Association v. FDA lawsuit ended in March 2025 with the FDA winning the right to enforce the end of mass-market compounding now that tirzepatide and semaglutide were off the shortage list. Mass-market 503B compounding effectively ended for these products. Some 503A compounding continued under the rules requiring individualized clinical need.

What this means for DTC GLP-1: legitimate platforms now document the individualized reason a patient needs compounded therapy rather than commercial product. Reasons might include allergy to a commercial-product excipient, need for a non-standard titration dose, or a combination formula with B12 or glycine.

Mass-market “$199 for any healthy adult” compounded programs faded. Platforms that adapted and document clinical need continue. Several platforms shut down or shifted to brand-name only.

How Are Payments Handled?

Most DTC GLP-1 platforms accept credit card, debit card, HSA card, and FSA card. A small number accept insurance for brand-name prescriptions. Compounded prescriptions are almost never billed to insurance.

Pricing models vary:

• Month-to-month subscriptions with no commitment
• Multi-month bundles (3-month, 6-month) at discounted per-month pricing
• Pay-as-you-go single prescriptions
• Introductory first-month pricing

Cancellation terms vary too. Read before signing up. Some platforms auto-renew and require explicit cancellation. A few have early-termination clauses on multi-month bundles.

What Follow-up Support Comes with DTC GLP-1?

Reputable platforms include:

• Asynchronous messaging with the clinical team for questions and side effects
• Dose adjustment reviews (typically at week 4 and after each step-up)
• Periodic check-ins at 1, 3, and 6 months
• Lab monitoring orders if clinically needed
• Refill management

Less reputable platforms ship the medication and disappear. Quality of follow-up correlates with overall platform quality. Ask about the support structure before signing up.

TrimRx’s personalized treatment plan includes the clinical team contact and follow-up schedule.

What’s the Regulatory Trajectory of DTC GLP-1?

The trend in 2024-2026 has been tightening, not loosening. The FDA pulled GLP-1s from the shortage list, the courts upheld the FDA’s enforcement, the FDA issued warning letters to gray-market vendors, and several state boards of pharmacy disciplined out-of-state compounders for unlicensed activity.

That doesn’t mean DTC GLP-1 is going away. It means the legal lane is narrower and the quality bar higher. Platforms that adapt to documentation requirements and partner with high-quality 503A pharmacies continue operating. The compliance bar is real, and that’s good for patients.

The next regulatory question is whether 503B compounding might return if a new shortage is declared. As of mid-2026, no shortage is officially declared, so 503B is closed for tirzepatide and semaglutide.

What Clinical Evidence Supports the DTC Model?

The clinical evidence supports the medications, not specifically the DTC delivery channel. STEP 1 (Wilding et al. 2021 NEJM), STEP 8, SURMOUNT-1 (Jastreboff et al. 2022 NEJM), SURMOUNT-2 (Garvey et al. 2023 Lancet), SELECT (Lincoff et al. 2023 NEJM), FLOW (Perkovic et al. 2024 NEJM), and SURMOUNT-OSA (Malhotra et al. 2024 NEJM) collectively establish efficacy and safety for the drugs.

DTC delivery is administratively different from traditional primary care but doesn’t change the clinical efficacy. The risks are the same: GI side effects (nausea, vomiting, diarrhea, constipation), gallbladder issues, rare pancreatitis, muscle mass loss without resistance training, contraindications around medullary thyroid carcinoma and MEN-2. Reputable DTC platforms screen for these the same way a primary care visit would.

Bottom line: Typical DTC timeline: intake to first injection 5-14 days; fastest platforms run 3-5 days

FAQ

Is Direct-to-consumer GLP-1 Safe?

Through reputable platforms with US-licensed clinicians and pharmacies, yes, with safety comparable to traditional primary care prescribing for most patients. Gray-market vendors operating without licensed clinicians are not safe.

Is DTC GLP-1 Legal in All 50 States?

Most platforms operate in most states. Telehealth prescribing rules vary by state. A few states have stricter requirements for synchronous video visits, in-state prescriber requirements, or controlled-substance-style rules. The platform will tell you whether your state is supported.

What’s the Difference Between LillyDirect and Compounded DTC?

LillyDirect dispenses FDA-approved Zepbound vials manufactured by Eli Lilly. Compounded DTC dispenses tirzepatide prepared by a US 503A pharmacy. The active ingredient is similar but the finished product is FDA-approved only for LillyDirect.

Do I Need to Do Anything Special for HSA Reimbursement with DTC GLP-1?

Save the itemized receipt from the platform showing date, medication, prescriber, and amount. Most platforms provide HSA-compatible receipts automatically.

Can I Switch From Brand-name DTC to Compounded DTC?

Yes, with a new intake at the compounded platform. The new clinician will write a new prescription. Your weight loss history transfers via self-report.

What Happens If I Have a Side Effect?

Message the clinical team. Reputable platforms have clinicians on call for urgent issues. Severe symptoms (persistent vomiting, severe abdominal pain, signs of pancreatitis) warrant emergency room evaluation, not a chat message.

Are DTC GLP-1 Prices Going to Drop in 2027?

Probably not significantly. Compounded pricing has stabilized around $200-500/month post-FOAF ruling. LillyDirect and NovoCare have set self-pay prices that are unlikely to drop dramatically. Generic semaglutide is years away.

Disclaimer: This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.